A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P),Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide. MonumenTAL-6
Objective
Primary Objective: to compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd.
Secondary Objectives: To further compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd. To characterize the PK of talquetamab and teclistamab. To assess the immunogenicity of talquetamab and teclistamab. To assess participants symptoms, functioning, and HRQoL with Tal-P, Tal-Tec, and EPd or PVd.
